Pacritinib and Octreotide: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Octreotide
Pacritinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
Avoid coadministration of pacritinib with a drug known to prolong QTc interval. Concomitant use of drugs that prolong the QT interval may add to the QTc interval prolonging effects of pacritinib, increasing the risk of cardiac arrhythmias. Avoid the use of pacritinib in patients with a baseline QTc of greater than 480 msec. If QT Interval prolongation greater than 500 msec or greater 60 msec from baseline, hold pacritinib. If QTc prolongation resolves to equal to or less than 480 msec or baseline within 1 week, restart pacritinib at the same dose. If time to resolution is greater than 1 week, restart pacritinib at a reduced dose. If unavoidable, correct hypokalemia prior to and during pacritinib treatment, manage QTc prolongation using pacritinib interruption and electrolyte management1.
Why it happens (mechanism)
Additive QT interval prolongation
Common questions
Can I take Pacritinib and Octreotide together?
An increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Pacritinib and Octreotide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Pacritinib or Octreotide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VONJO(R) oral capsules, pacritinib oral capsules. CTI BioPharma Corp (per FDA), Seattle, WA, 2024. DailyMed
Keep reading about Octreotide
Keep reading about Pacritinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist